RecruitingNCT07531719
Neurological
Multiple System Atrophy
Also known as MSA, Shy-Drager syndrome, striatonigral degeneration, olivopontocerebellar atrophy
Multiple system atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by alpha-synuclein accumulation in oligodendrocytes (glial cytoplasmic inclusions). It affects the autonomic nervous system, cerebellum (M
ORPHA:102 ↗Gene SNCA (risk geneGene not causative in most cases)Prevalence 1-5 per 10,000 (Orphanet)Onset AdultSporadic (genetic risk factors identified)
89
studies recruiting now
as of 7 Sept 2026
461
studies registered in total
as of 7 Sept 2026
9
countries with a recruiting site
as of 7 Sept 2026
22 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT06596746
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
RecruitingPhase 1NCT07604116
A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
RecruitingPhase 2NCT07197866
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RecruitingPhase 1NCT06683365
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 89 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Multiple System Atrophy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: MSA Coalition Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Multiple System Atrophy
Multiple system atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by alpha-synuclein accumulation in oligodendrocytes (glial cytoplasmic inclusions). It affects the autonomic nervous system, cerebellum (MSA-C subtype), and/or the nigrostriatal system (MSA-P subtype). Key features include autonomic failure (orthostatic hypotension, urogenital dysfunction), cerebellar ataxia, and parkinsonism poorly responsive to levodopa. Median survival from onset is 6-10 years.
Common clinical features
Orthostatic hypotensionCerebellar ataxiaParkinsonism (levodopa-unresponsive)Urinary incontinenceREM sleep behavior disorderVocal cord dysfunctionInspiratory stridor
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
2 approved treatments and 18 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Droxidopa (Northera)Approved: Ioflupane I 123 (Celsunax)
Phase 3Riluzole (Exservan)
Phase 3Rifampin (Eremfat)
Phase 3Verdiperstat
Phase 3Amlenetug
Phase 3Epigalocatechin Gallate
Phase 2Inosine
Phase 2Lithium Carbonate (Camcolit 250)
Phase 2Foralumab
+ 10 more in development
Before you apply
Things trial teams commonly ask about for Multiple System Atrophy. Not eligibility rules; those are set by each study.
- Probable MSA diagnosis per second consensus criteria is typically required — document clinical phenotype (MSA-C vs MSA-P)
- Levodopa response testing (non-response or minimal response) is a diagnostic confirmation marker required for enrollment
- Plasma neurofilament light chain (NfL) and alpha-synuclein seed amplification assay (SAA) are emerging eligibility biomarkers
- Autonomic function testing (tilt table, QSART, urodynamics) is standard at baseline and for outcome monitoring
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).